Challenges & Opportunities For Neoantigen Cell-Based Therapy
Tuesday 13 April - 09.00 - 15.00
This focus day aims to delve deep into the promise, the progress and the pitfalls related to weaponising neoantigen cell-based immunotherapies.
Much of the neoantigen field is dominated by efforts towards personalised vaccines; this session is solely focused on the challenges and opportunities related to neoantigen cell-based therapy.
9:00 am Chairs Opening Remarks
Synopsis• Setting the scene: Why choose personalised cell therapy over personalised vaccines? • Quick introduction as to why neoantigen cell therapy is behind neoantigen vaccine development in terms of number of active clinical trials • Why pioneers in this space believe that cell therapy will soon surpass vaccines
9:10 am Novel Approaches for More Effective Neoantigen Identification
- Alena Gros Principal Investigator, Tumor Immunology & Immunotherapy, Vall d’Hebron Institute of Oncology
• Development of novel personalised T cell therapies for cancer treatment
• Optimizing neoantigen discovery: Identifying neoantigens, isolating T-cell subsets
• Identification of neoantigen-specific TCRs
• Combining tandem minigene screens and peptide pool screens for neoantigen identification
9:40 am Delving into the Properties of T-Cell Recognised Neoantigens
- Pia Kvistborg Junior group leader, Department of Immunology, The Netherlands Cancer Institute
• Leveraging an in-silico prediction pipeline
• Identifying T cell recognized neoantigens
• Elucidating properties that may lead to T cell recognition
• How can we use this platform to help predict immunogenicity
10:10 am Leveraging Neoantigens for Personalised TCR Gene Therapy
- Joost van den Berg Head of facility – Pharmacist, Netherlands Cancer Institute
• Characterising NEON antigen reactivity in TIL products and in blood of treated patients
• How TCR gene therapy compares to TIL therapy
• Developing a neoantigen directed T cell products: a new generation of personalized T cell therapy
10:40 am Morning Refreshments and Speed Networking
11:40 am Engineered T cells for the Treatment of Malignancy
- Jennie Lill Senior Director of Proteomics & NGS, Genentech
• Challenges with current therapeutic modalities, and why engineered T cell therapeutics are an attractive option
• Challenges and improvements to in silico based prediction methods for selecting epitopes for generating TCRs against
• Current strategy for selecting epitopes for engineering T cells against using a combination of biochemical and mass spectrometric
12:20 pm Designing Best in Class TCR Cell Therapies Against Novel Antigens
- Luke Lee CEO, Co-Founder, 3T Biosciences
• Identifying the nuances of neoantigen TCR-based therapies to allow acceleration to the clinic
• Importance of diversity for identifying first in class targets and best in class T cell receptors while minimizing off-target toxicity.
• Characterizing T cell receptors with the ideal binding profile.
• Utilization of a mass spectrometry independent yeast display platform that leverages in silico based prediction models to de-risk T
cell receptor cell therapies.
12:50 pm Networking Lunch
1:50 pm Roundtable Discussions:
Assessing combinatorial approaches to successful personalized T-cell therapy
Identifying where the challenges lie in targeting shared neoantigens for TCR based off the-shelf immunotherapy
How can we overcome clinical & logistical challenges in neoantigen based TCR therapy